Determination of (4E,6E,12E)-Tetradecatriene-8,10-diyne-1,3-diyl Diacetate in Rat Plasma and Tissues by HPLC-UV Method and Their Application to a Pharmacokinetic and Tissue Distribution Study

Table 3

The tissue concentrations of (4E,6E,12E)-tetradecatriene-8,10-diyne-1,3-diyl diacetate after oral administration raw and processed Atractylodis Rhizoma at a dose of 40 g·kg⁻¹ to rats, respectively (𝜇g/g).

Tissues	0.5 h		2 h		4 h		8 h
	Raw	Processed	Raw	Processed	Raw	Processed	Raw	Processed
Heart	125.31	137.68	128.97	244.30	77.35	61.62	35.94	30.56
Liver	80.37	158.37	155.10	208.56	158.07	173.38	115.10	128.98
Spleen	170.71	119.41	253.18	292.69	186.45	204.92	17.34	30.66
Lung	69.35	70.01	46.54	174.26	84.79	100.26	40.20	60.61
Kidney	108.76	105.54	76.15	242.21	81.83	84.78	24.51	21.12
Stomach	112.31	107.95	109.77	122.96	65.22	78.53	43.17	59.93
Large Intestine	20.33	30.68	79.02	54.78	112.25	143.34	166.77	176.64
Small Intestine	91.25	106.29	139.04	115.53	191.22	159.02	44.91	54.78